Anti-trypanosomatid drug discovery: progress and challenges

Area of Science:

• Neglected tropical diseases
• Drug discovery
• Parasitology

Background:

• Leishmaniasis, Chagas disease, and human African trypanosomiasis cause significant global health burdens, especially in low- and middle-income nations.
• While human African trypanosomiasis treatment has improved, leishmaniasis and Chagas disease urgently require novel therapeutic agents.
• The drug development pipeline for Chagas disease is notably underdeveloped, necessitating focused research and investment.

Purpose of the Study:

• To review recent advancements in understanding the biology of pathogens causing leishmaniasis, Chagas disease, and human African trypanosomiasis.
• To explore progress in developing new drug candidates and identifying viable molecular targets for these diseases.
• To discuss existing challenges in clinical candidate development and propose strategies for overcoming them.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of drug discovery perspectives and biological insights into causative pathogens.
• Exploration of clinical development pipelines and molecular target identification.

Main Results:

• Recent biological discoveries offer new avenues for drug development against neglected tropical diseases.
• Several promising drug candidates and molecular targets have been identified for leishmaniasis and Chagas disease.
• Significant challenges persist in advancing these candidates through clinical trials.

Conclusions:

• Continued research into pathogen biology is essential for advancing drug discovery for leishmaniasis and Chagas disease.
• Addressing challenges in clinical development, such as funding and regulatory hurdles, is critical for bringing new treatments to patients.
• Collaborative efforts are needed to accelerate the development of urgently required medicines for these neglected diseases.